CIK 0001447028 · Non-accelerated filer<br>Smaller reporting company
Arbutus Biopharma Corp
Sign in to watch- Ticker
- ABUS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980597776
- Phone
- 604-419-3200
- Business address
- 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
- Former names
- TEKMIRA PHARMACEUTICALS CORP, TEKMIRA PHARMACEUTICALS Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-02 | Sofia Michael J. Chief Scientific Officer | Sale 10b5-1 | −9,982 | $2.31 | $23K | 1,485,121 |
| 2024-02-02 | McElhaugh Michael J. Interim President & CEO | Sale 10b5-1 | −10,164 | $2.31 | $24K | 1,504,793 |
| 2024-02-01 | Naftzger J. Christopher General Counsel and CCO | Grant or award | +95,100 | 95,100 | ||
| 2024-02-01 | Naftzger J. Christopher General Counsel and CCO | Grant or award · Stock Option (Right to Buy) | +380,500 | 380,500 | ||
| 2024-02-01 | Sims Karen Chief Medical Officer | Grant or award 10b5-1 | +101,000 | 129,900 | ||
| 2024-02-01 | Sims Karen Chief Medical Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +403,900 | 403,900 | ||
| 2024-02-01 | HASTINGS DAVID C Chief Financial Officer | Grant or award 10b5-1 | +112,500 | 191,500 | ||
| 2024-02-01 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +450,000 | 450,000 | ||
| 2024-02-01 | Sofia Michael J. Chief Scientific Officer | Grant or award 10b5-1 | +109,500 | 1,495,103 | ||
| 2024-02-01 | Sofia Michael J. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +437,800 | 437,800 | ||
| 2024-02-01 | McElhaugh Michael J. Interim President & CEO | Grant or award 10b5-1 | +123,800 | 1,514,957 | ||
| 2024-02-01 | McElhaugh Michael J. Interim President & CEO | Grant or award · Stock Option (Right to Buy) 10b5-1 | +495,100 | 495,100 | ||
| 2023-07-12 | Rewolinski Melissa Director | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2023-07-10 | Sims Karen Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +153,640 | 153,640 | ||
| 2023-07-10 | Naftzger J. Christopher General Counsel and CCO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-05-24 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2023-05-24 | BURGESS DANIEL D Director | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2023-05-24 | MANCHESTER KEITH S Director | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2023-05-24 | Torti Frank Director | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2023-05-24 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 |
Page 4 of 8 · 141 trades